Setting new standards in information exchange for the pharmaceutical and biotech industry
Alnylam Pharmaceuticals’ Akshay Vaishnaw, MD, PhD to Deliver Keynote Address at Boston’s Chief Medical Officer Summit
March 27, 2016
Following numerous recommendations, we are delighted to announce: Akshay Vaishnaw, MD, PhD, EVP of R&D, and CMO, Alnylam Pharmaceuticals has been confirmed as a keynote speaker for the 4th Annual Chief Medical Officer Summit on May 11-12th in Boston, MA.
Dr Vaishnaw will address the “Challenges and Opportunities in Pursuing a New Therapeutic Modality from its Inception”. As the CMO at a leading RNAi therapeutics company Dr Vaishnaw is perfectly positioned to offer valuable insights into what to expect from undertaking a new therapeutic modality.
About Akshay Vaishnaw, MD, PhD
Dr Akshay Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc (now Biogen Idec Inc), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Akshay received his MD from the University of Wales College of Medicine, UK, with Distinctions in Pathology and Medicine, and his PhD from the University of London, UK, in Molecular Immunology. He is a Member of the Royal College of Physicians, UK. Akshay is a member of the Scientific Advisory Board of Scholar Rock, and a member of the Board of Directors for Visterra, Inc. In addition, he has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.